Risk factor
Poor trading liquidity
Profitability factor
Undervalued vs peers
About
Based in Seoul, South Korea, CMG Pharmaceutical Co., Ltd. operates as a pharmaceutical firm dedicated to the research, development, and sale of innovative oral thin film (OTF) medications. Its diverse product portfolio features OTF formulations such as Tadalafil for addressing erectile dysfunction, Entecavir for managing hepatitis B, Aripiprazole for treating schizophrenia, and Montelukast for alleviating asthma and allergic rhinitis. The company also engages in a strategic partnership with Handok Inc., focusing on advancements in cancer treatment. Established in 2001, the enterprise was formerly recognized as Skynewpharm Co Ltd before officially becoming CMG Pharmaceutical Co., Ltd. in April 2013.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA.